Observational studyRheumatology (Oxford, England)2025
Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal symptoms: a prospective and multicentre study.
Observational study in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesTo evaluate clinical and ultrasound (US) features related to psoriatic arthritis (PsA) development in psoriasis (PsO), patients without musculoskeletal (MSK) symptoms and no systemic treatment.
methodsProspective study including PsO patients followed by dermatologists. Clinical and US data were collected at baseline and during follow-up by rheumatologists.
resultsSeventy-eight patients with PsO were included. Mean disease duration was 15.1 years (SD ± 13.4); most had mild PsO (82%), onychopathy was present in 36 (39.7%) and overweight/obesity in 38 patients (48.7%). In the US evaluation, nine patients (11.5%) had Power Doppler grade 1 at joints, 56.4% had calcifications and 30.4% bursitis at enthesis. Sixty patients completed the study. After a median of 76.60 months (IQR 39.34-85.25), 34 patients (56.6%) developed MSK symptoms. They had higher BMI (P = 0.013), abdominal circumference (P = 0.022), scored higher for pain (P = 0.047) and fatigue (P = 0.011). Their baseline US showed a higher total US score (P = 0.037). Five patients (8.3%) developed MSK inflammatory symptoms, and four met CASPAR criteria (5.5%). The mean time from baseline to PsA diagnosis was 20.20 months (SD ± 12.02). US bursitis was present in 80% of patients developing inflammatory symptoms (P = 0.049).
conclusionsIn a cohort of patients with mild PsO, systemic therapy-naive and no MSK symptoms, incidence of PsA was 1% per year. US bursitis at enthesis was related to the development of symptoms suggestive of PsA. Patients who developed MSK symptoms had higher BMI, fatigue and pain VAS scores at baseline and could constitute a subgroup with higher risk for transition to PsA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.